Seoul Pharma Co., Ltd., (the ''SPC'') has engaged in manufacturing and distribution of pharmaceuticals since its establishment in 1976 and established the Centralized R&D Centre in 1997 for the purpose of R&D on new drug delivery technology.

SPC?s sales revenue reached to KR\\43.8Billion in 2014, showing more than 2% of CAGR for the past five years, when comparing its KR\\40.4Billion in 2010. SPC has produced more than 50 oral solid products mainly as Rx with such therapeutic categories as respiratory, infective, cardio-vascular, gastro-intestinal, endocrinal, anti-obesity, and so on.

Throughout the 24 branch offices in Korea, SPC?s distribution activity has mainly been focused on clinic market, having the products of SEBRON(anti-tussive, acetylcysteine), TORHES-F(digestive, trimebutine), DUVELAC(probiotics), AUCLATIN (antibiotic, amoxicillin and potassium clavulanate), DIFLU(antifungal, fluconazole), EXLIP ER(dyslipidemic, nicotinic acid), and so on. SPC was designated as a Venture company in 2000 and listed on the KOSDAQ, then in 2002 and 2003, and selected as a Promising export and INNO-BIZ company by Korean government authorities respectively.

Based on more advanced technology and accelerating R&D activities with number of R&D Pipeline including NME, IMD, and so on, SPC has developed and launched many IMD products, such as ?EXLIP ER? of hyperlipidemic agent as extended-released type in 2006 and amino-acids supplementary suspension ?ALIVER? in 2012.